Teleflex Incorporated (TFX) was Reiterated by Barclays to “Overweight” according to the research note released today. The brokerage firm has raised the Price Target to $ 183 from a previous price target of $170 . Barclays advised their investors in a research report released on Jun 14, 2016.
Many Wall Street Analysts have commented on Teleflex Incorporated. Company shares were Reiterated by Barclays on Apr 29, 2016 to “Overweight”, Firm has raised the Price Target to $ 170 from a previous price target of $155 .
On the company’s financial health, Teleflex Incorporated reported $1.52 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.35. The company had revenue of $424.90 million for the quarter, compared to analysts expectations of $423.03 million. The company’s revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.30 EPS.
Teleflex Incorporated opened for trading at $173.05 and hit $174.98 on the upside on Friday, eventually ending the session at $174.79, with a gain of 1.20% or 2.08 points. The heightened volatility saw the trading volume jump to 3,81,538 shares. Company has a market cap of $7,620 M.
In a different news, on Jun 7, 2016, Stuart A Randle (director) sold 797 shares at $166.10 per share price. According to the SEC, on May 18, 2016, Thomas Anthony Kennedy (Senior VP, Global Operations) sold 15,102 shares at $160.20 per share price. On Aug 21, 2015, Patricia C Barron (director) sold 1,500 shares at $132.74 per share price, according to the Form-4 filing with the securities and exchange commission.
Teleflex Incorporated is a provider of medical technology products. The Company designs develops manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company also markets and sells its products to hospitals and healthcare providers. The Company operates its business in six segments: Vascular North America; Anesthesia/Respiratory North America; Surgical North America; Europe the Middle East and Africa (EMEA); Asia and Original Equipment Manufacturer (OEM). The Company manufactures its products at 26 manufacturing sites with manufacturing operations located in the Czech Republic Germany Malaysia Mexico and the United States. The Companys specialty product line consists of a range of catheters including Foley intermittent external and suprapubic; urine collectors; catheterization accessories and products for operative endourology.